Aptadir

CE-Ventures has led a €40 million seed round for Aptadir Therapeutics, described as one of the largest seed investments in European biotech. The funding will support the early-stage therapeutics company as it advances its pipeline. The size of the round at seed stage stands out in a market where biotech funding has become more selective, drawing attention from investors and industry watchers.

Aptadir Therapeutics, a biotech startup based in Milan, has raised a $45 million seed funding round, one of the larger early-stage raises in the European biotech sector. The funding gives the young company substantial resources to advance its research and development programs, and highlights growing investor appetite for Italian and European life sciences ventures.

Spanish biotech Aptadir has secured a €40 million funding package to advance its demethylating medicines, a class of therapies targeting epigenetic changes in cancer cells. The company says the new capital will support development of its pipeline of epigenetic drug candidates as it moves toward clinical progress.